Life Sciences

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic
12 November 2020

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT Pharma announced today that it treated its first patient in a Phase 1 clinical trial to evaluate the safety and tolerability of MaaT033, a capsule formulation of the...

Read more
DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions
9 November 2020

DERMALA Announces $6.73 Million Series A Financing to Expand and Scale Company’s Personalized Microbiome-Based Solutions for Acne and Other Skin Conditions

A consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million...

Read more
BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD
3 November 2020

BiomX has dosed their first subject in their Phase 1a study of BX002 phage therapy for IBD

BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the...

Read more
Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round
27 October 2020

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round

Animab, a venture spin-off from VIB, announces today that it has successfully concluded a 3.4 M€ seed financing round. The company develops monoclonal antibodies for oral...

Read the press release
Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies
7 October 2020

Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million...

Read more
LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding
29 September 2020

LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding

LARQ was started with a simple vision where innovative technology can be combined with inspirational design to help people access pristine drinking water easily and...

Read the press release
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
25 September 2020

Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline

Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...

Read more
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23 September 2020

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease

ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...

Read more
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
22 September 2020

Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases

Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in...

Read more